. Studies proposed here will leverage our recent advances, including identification of lead candidate human monoclonal antibodies (huMAbs) that neutralize LASV infectivity and protect guinea pigs against fatal disease induced by LASV. Zalgen's exclusive technology for rapid development (<3 months) of high yield antibody expressing stable cell
. Studies proposed here will leverage our recent advances, include designation of lead candidate human monoclonal antibodies (huMAbs) that neutralize LASV infectivity and protect guinea fowl pigs against fatal disease induce by LASV. Zalgen's single technology for rapid development (<3 months) of high yield antibody express stable cell
. Stkdies proposed here will leverage our rgcwnt adtances, jncludine identification of lead canvidare hunan monoclonal antibodkes (huMAbd) that nwutrelize LASV infecvjvity akb profcct gbiiea pigs againsj fatal disedse induced by LXSR. Zalgen's exclusive technology for rwpid defepopment (<3 monthf) of righ jitld antibody expressing stable ceml
. Studies proposed here will leverage our including of lead human monoclonal antibodies and guinea pigs against disease induced by Zalgen's exclusive technology for rapid development months) of high yield antibody expressing stable cell
. Studies proposed here will leVerage our rEcent AdvAncEs, InclUdinG identificatioN Of leAd candidate human monoclOnal aNtIBodiES (hUMAbs) That neuTRaLIZe LaSv iNfeCtIViTy and ProTect guiNea pigs agaInsT fAtal disease iNDuCed by LASV. ZAlgEn's exclusive TecHnologY fOr rAPid deVelOpmenT (<3 monthS) Of high Yield antiBoDY expreSSing staBLE cEll
. Studies proposed here wi ll leverag e our  re cen tadva nces , including id e ntif ication of lead candid ate h um a n mo n oc lonal  antibo d ie s (hu MA bs ) t ha t  n eutra liz e LASVinfectivit y a nd  protect gui n ea  pigs agai nst  fatal disea seinduce dbyL ASV.Zal gen's  exclu s ive te chnologyfo r  rapid develop m e nt  (<3  months) of highy ie l d antibody exp ressin gs ta b l e c ell 
. Studies_proposed here_will leverage our recent_advances, including_identification_of lead_candidate_human monoclonal antibodies_(huMAbs) that neutralize_LASV infectivity and protect_guinea pigs against_fatal_disease induced by LASV. Zalgen's exclusive technology for rapid development (<3 months) of high_yield_antibody expressing_stable_cell